Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation …
JAC Sterne, PN Bodalia, PA Bryden… - Health Technology …, 2017 - discovery.ucl.ac.uk
… Aspirin or no pharmacotherapy were likely to be the most cost-effective … Cost-effectiveness
acceptability curves for sensitivity analysis comparing lower doses of apixaban and dabigatran…
acceptability curves for sensitivity analysis comparing lower doses of apixaban and dabigatran…
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
K Bowrin, JB Briere, L Fauchier, C Coleman, A Millier… - PLoS …, 2020 - journals.plos.org
… effectiveness (VKA rates and comparative effectiveness). A previous … 18 cost-effectiveness
models comparing rivaroxaban and other NOACs with VKAs for stroke prevention in patients …
models comparing rivaroxaban and other NOACs with VKAs for stroke prevention in patients …
A systematic literature review on the cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation
C Pinyol, JM Cepeda, I Roldan, V Roldan… - Cardiology and …, 2016 - Springer
… of apixaban versus warfarin and aspirin or other new oral … to directly compare the ICERs of
cost-effectiveness analysis included. … Cost effectiveness of new oral anticoagulants for stroke …
cost-effectiveness analysis included. … Cost effectiveness of new oral anticoagulants for stroke …
Cost-Effectiveness analysis of direct-acting oral anticoagulants for stroke prevention in Thai patients with Non-Valvular atrial fibrillation and a high risk of bleeding
T Rattanachotphanit, C Limwattananon… - …, 2019 - Springer
… oral anticoagulants (DOACs), including apixaban, dabigatran… , anticoagulants were
discontinued and replaced with aspirin… performed by comparing an outcome of patient survival in …
discontinued and replaced with aspirin… performed by comparing an outcome of patient survival in …
Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients
E Walter, M Voit, G Eichhober - Expert Review of …, 2021 - Taylor & Francis
… with NVAF in the ARISTOTLE study [Citation10] and versus aspirin … cost-effectiveness
analyses of apixaban in comparison with other DOACs (apixaban, dabigatran 110mg, dabigatran …
analyses of apixaban in comparison with other DOACs (apixaban, dabigatran 110mg, dabigatran …
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Economic Evaluations
Z Goudarzi, MG Darab, A Vazin, A Hayatbakhsh… - Value in Health …, 2023 - Elsevier
… about the cost-effectiveness of new oral anticoagulants. … warfarin with 3 comparative arms
of apixaban, dabigatran, and … confirmed the cost-effectiveness of dabigatran over rivaroxaban. …
of apixaban, dabigatran, and … confirmed the cost-effectiveness of dabigatran over rivaroxaban. …
Cost effectiveness of apixaban versus warfarin or aspirin for stroke prevention in patients with atrial fibrillation: a Greek perspective
K Athanasakis, N Boubouchairopoulou… - American Journal of …, 2017 - Springer
… novel oral anticoagulant apixaban represents a cost-effective option versus aspirin and
warfarin for the prevention of stroke … the comparative cost effectiveness of apixaban from …
warfarin for the prevention of stroke … the comparative cost effectiveness of apixaban from …
Comparing the cost effectiveness of non-vitamin K antagonist oral anticoagulants with Well-Managed warfarin for stroke prevention in atrial fibrillation patients at high …
… prevent stroke in AF: dabigatran, rivaroxaban, apixaban, and edoxaban. NOACs have become
a focus of many cost-effectiveness … with aspirin and one of the oral anticoagulant agents. …
a focus of many cost-effectiveness … with aspirin and one of the oral anticoagulant agents. …
Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
K Bowrin, JB Briere, P Levy, A Millier… - Journal of Market …, 2020 - Taylor & Francis
… of oral anticoagulation treatment for the prevention of stroke in … (dabigatran etexilate) and
factor Xa inhibitors (rivaroxaban, … comparative treatment effect for rivaroxaban and apixaban vs …
factor Xa inhibitors (rivaroxaban, … comparative treatment effect for rivaroxaban and apixaban vs …
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review
NL Liberato, M Marchetti - Expert Review of Pharmacoeconomics …, 2016 - Taylor & Francis
… cost-effectiveness of dabigatran, apixaban, rivaroxaban and … -AF, a trial comparing
Rivaroxaban 20 mg once daily versus … Apixaban has been also compared to acetylsalicylic acid (…
Rivaroxaban 20 mg once daily versus … Apixaban has been also compared to acetylsalicylic acid (…